.jpg)
L-Demethyl Phencynonate Hydrochloride, also known as LS001, is a small molecule drug that has been gaining attention in the medical world. This article provides an in-depth overview of the drug's research and development.
Drug Basics
LS001, scientifically known as L-Demethyl Phencynonate Hydrochloride, falls under the category of small molecule drugs. This medication has the following properties:
Drug Type: Small Molecule Drug
Synonyms: R-DM8021, LS001, LS 001
Target: M4 receptor(Muscarinic acetylcholine receptor M4)
Mechanism: M4 receptor antagonists(Muscarinic acetylcholine receptor M4 antagonists)
Therapeutic Areas: Nervous System Diseases, Endocrinology, and Metabolic Disease
Active Indication: Parkinson's Disease
Structure: Molecular Formula C21H29NO3
CAS Registry: 860644-53-7
Clinical Trials & Research
LS001 has been subjected to five clinical trials to ascertain its safety, tolerability, and efficacy in treating Parkinson's disease.
Phase I Clinical Study
The primary aim of the Phase I clinical study was to assess the safety and tolerance of LS001 in patients in the early and middle stages of Parkinson's disease. Additionally, these trials also aimed to evaluate the pharmacokinetic characteristics and therapeutic effectiveness of LS001. Moreover, the study endeavored to explore the metabolites of LS001 within patients suffering from Parkinson's disease.
Randomized, Double-Blind, Placebo-Controlled Study
Another significant study was a randomized, double-blind, placebo-controlled investigation designed to explore the dosage and tolerability of LS001 in treating patients in the early and middle stages of Parkinson's disease.
The main objective of this study was to assess the safety and tolerability of LS001 in the same patient group. The secondary objective was to gauge the preliminary efficacy of LS001 in treating early-stage and middle-stage Parkinson's disease and to evaluate the population pharmacokinetic characteristics of this disease group.
Patent Information
LS001 has been associated with 100 patents in the medical field, indicating the substantial research and development efforts behind this drug.
R&D Status and Core Patent Data
The R&D status of LS001 is of great interest to researchers and medical professionals alike. Information regarding the core patent data can significantly enhance research initiatives.
Clinical Trial Analysis
Comprehending the most recent clinical trials across global registries is crucial to understanding the potential of LS001.
Regulatory Approval Information
Understanding the latest regulatory approval information can accelerate research efforts and give a clear picture of the drug's standing in the medical field.
Drug Designations
Understanding the key drug designations is essential, and with tools like Synapse, this information can be accessed in just a few clicks.
In conclusion, LS001 is a promising drug in the field of neurology and endocrinology. Its potential to treat Parkinson's disease has been proven through various clinical trials, and further research and development could open new doors in the medical field.
Comments